换一批
换一批YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
第一作者：
Qian,Lei
第一单位：
Lab of Medicinal Chemistry, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, 610041, Chengdu, China.
作者：
主题词
乙酰胺类(Acetamides);抗肿瘤药(Antineoplastic Agents);乳腺肿瘤(Breast Neoplasms);CDC2蛋白激酶(CDC2 Protein Kinase);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);中心粒(Centrioles);周期素依赖激酶抑制剂p21(Cyclin-Dependent Kinase Inhibitor p21);药物评价, 临床前(Drug Evaluation, Preclinical);女(雌)性(Female);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);人类(Humans);吲唑类(Indazoles);有丝分裂(Mitosis);蛋白激酶抑制剂(Protein Kinase Inhibitors);嘧啶类(Pyrimidines);RNA, 小分子干扰(RNA, Small Interfering);信号传导(Signal Transduction);存活率分析(Survival Analysis);肿瘤负荷(Tumor Burden);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays);cdc25磷酸酶类(cdc25 Phosphatases)
DOI
10.1038/s41419-018-1071-2
PMID
30337519
发布时间
2021-12-04
- 浏览13
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
